Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 9/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14000549 | 1.00 | SCN4A (0.52) | SCN4AGSRTACR1PTGS2 | |
| SCHEMBL8957372 | 0.82 | GSR (0.50) | GSRPTGS2 | |
| SCHEMBL9872237 | 0.79 | GSR (0.47) | GSRTACR1PTGS2 | |
| SCHEMBL9803273 | 0.76 | GSR (0.67) | GSRPTGS2 | |
| SCHEMBL2782707 | 0.75 | SCN4A (0.68) | SCN4ATACR1 | |
| SCHEMBL4588667 | 0.75 | EPHX1 (0.53) | SCN4ATACR1 | |
| SCHEMBL4588669 | 0.75 | GSR (0.44) | SCN4AGSRPTGS2 | |
| SCHEMBL9198000 | 0.75 | NPC1 (0.51) | SCN4AGSR | |
| SCHEMBL22051985 | 0.73 | SCN4A (0.65) | SCN4ATACR1 | |
| SCHEMBL8957388 | 0.72 | GSR (0.47) | GSRPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | SCN4A 3814/4885GSR 40/4885TACR1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.